Fig. 2From: Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trialsTime to (a) first investigator-reported and (b) adjudicated confirmed or suspected acute exacerbation reported as a serious adverse event in patients treated with nintedanib or placeboBack to article page